3913-19-7

Usage

Uses

Used in Pharmaceutical Research and Development:
6-Bromo-2-chloro-4-methylquinoline is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly those with potential anti-malarial, antibacterial, and cytotoxic properties. Its unique structure allows for the exploration of new drug candidates that could address unmet medical needs.
Used in Chemical Synthesis:
In the field of organic chemistry, 6-bromo-2-chloro-4-methylquinoline serves as a valuable building block for the synthesis of more complex molecules. Its reactivity and the presence of halogen substituents make it a versatile compound for use in the creation of novel chemical entities.

Upstream product

• 1336-21-6 ammonium hydroxide 
• 7440-44-0 pyrographite 
• 89446-19-5 6-bromo-4-methyl-1,2-dihydroquinolin-2-one 
• 106-40-1 4-bromo-aniline 
• 38418-24-5 N-(4-bromophenyl)-3-oxobutyramide 

Downstream Products

• 1187386-12-4 6-bromo-4-methyl-2-methoxyquinoline 
• 89446-22-0 (Z)-2-(2-Dimethylamino-4-methyl-quinolin-6-ylmethyl)-3-phenylamino-acrylonitrile 

Relevant academic research and scientific papers

On the Knorr synthesis of 6-bromo-4-methylquinolin-2(1H)-one

In the course of our work on infectious diseases, we were led to prepare 6-bromo-2-chloro-4-methylquinoline as a starting material. Since surprisingly little has been reported in the literature, the two synthetic steps to this compound were investigated. The synthesis involves a condensation between -keto esters and 4-bromoaniline and the cyclization of the resulting anilides into 6-bromoquinolin-2(1H)-one, otherwise known as the Knorr reaction. The 1H NMR monitoring of the first step allowed us to optimize the conditions leading specifically to the anilide without the occurrence of the alternative crotonate. To illustrate the scope of our finding, few additional anilides featuring electron-attracting groups were prepared. The study of their cyclization revealed some unsuspected steric effect governing this second step. Aside from rectifying a few claims in this chemistry, this study led to a three-step preparation of 6-bromo-2-chloro-4-methylquinoline in 48% overall yield from 4-bromoaniline. Georg Thieme Verlag Stuttgart - New York.

HYDRAZONE COMPOUNDS AND THEIR USE

The present invention relates to hydrazone compounds of Formula I: (I) and pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3, R4, L1, and L2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I as inhibitors of TRPM5 protein.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity and diabetes.

2,4-Diamino-5-benzyloxypyrimidines and Analogues as Antibacterial Agents. 11. Quinolylmethyl Analogues with Basic Substituents Conveying Specificity

A series of nine 2,4-diamino-5-pyrimidines has been prepared by condensations of quinolinecarboxaldehydes with β-anilinopropionitriles, followed by treatment with guanidine.All compounds had basic or methoxy substituents at the 2-

2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials

Compounds of the formula (II) STR1 or a salt, N-oxide or acyl derivative thereof, wherein Y is a group STR2 which is optionaly substituted and which optionally contain a nitrogen atom at one of positions A, B, C, D or E, in which the dotted line represents aromatic rings unless one of the rings contains a nitrogen atom in which case this ring is either aromatic or partially saturated, have antimicrobial properties. Processes for making these compounds, pharmaceutical compositions containing them and the medical use of the compounds are also disclosed.